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There are conflicting results on the association between thyroid function and incident dementia. An increased risk of dementia in patients with hypothyroidism has been found in some studies. For example, one study of patients with Alzheimer's dementia (AD) found hypothyroidism to be overrepresented among those patients with dementia \[[@CR1]\], while another study did not find hypothyroidism to be associated with AD pathology but instead with cerebrovascular diseases and thus with vascular dementia (VaD) \[[@CR2]\].

However, there are possible mechanisms supporting the association between hypothyroidism, thyroid hormones and dementia. Thyroid hormones certainly are involved in the development and maturation of the brain in early life, and the lack of thyroid hormones has deleterious effects on the brain in congenital hypothyroidism \[[@CR3], [@CR4]\]. Thyroid hormones could also exert an effect on the adult brain, e.g. showing a positive effect on memory in euthyroid men \[[@CR5]\], and with thyroid hormones showing improvement in hippocampus function \[[@CR6]\], and an augmentation of cholinergic activity \[[@CR7]\].

Atrial fibrillation (AF) is increasingly common with age and has also been shown to be associated with a higher dementia risk \[[@CR8]--[@CR10]\], where the most important factor is the increased risk of cardio-embolic stroke \[[@CR10]\]. In accordance with this, anticoagulant treatment has been shown to be associated with a lower risk of dementia in patients with AF in observational studies \[[@CR11], [@CR12]\]. To use a population of patients with AF, as they are generally prescribed many cardiovascular drugs, is also a way to test if levothyroxine may affect the development of dementia in patients with complex cardiovascular pharmacotherapies. For example, antihypertensive drugs have been shown to reduce the risk of dementia, such as thiazides in combination with a RAS-blocker (ACE-inhibitor or angiotensin-receptor blockers, ARBs) in patients with AF \[[@CR13]\], and calcium channel blockers and ARBs in older people \[[@CR14]\].

The relation between hypothyroidism, levothyroxine, and mortality has been elucidated in earlier research, where hypothyroidism and levothyroxine treatment was associated with a lower cardiovascular risk and mortality \[[@CR15]\], even if the potential mechanism explaining the association between levothyroxine treatment and mortality is unknown.

Women are known to exhibit a higher prevalence of hypothyroidism and thus of levothyroxine treatment than men \[[@CR16]\]. Besides, women with AF are also found to have a higher relative risk of stroke than men \[[@CR17]\]. Hence, men and women should be analyzed separately.

The primary aim was to study the association between levothyroxine treatment and dementia among patients with AF in Sweden.

Methods {#Sec2}
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We examined information on individuals from Swedish population-based registers with national coverage. These registers were linked, using each person's unique identification number, replaced by a serial number to preserve confidentiality. The study population was defined from the Swedish Total Population Register at Statistics Sweden, which also delivered the individual socioeconomic variables. The Inpatient Register, the Swedish Prescribed Drug Register and the Swedish Cause-of-Death Register were obtained from The National Board of Health and Welfare. These registers contain individual-level data on age, gender, education, hospital admissions, mortality and cause-of-death for all residents registered in Sweden. Ethical approvals were obtained from regional boards at Karolinska Institutet and the University of Lund.

The study included all patients with diagnosed AF, identified by the presence of the ICD-10 code (10th version of the WHO's International Classification of Diseases) for atrial fibrillation (I48) in the Swedish Hospital register from January 1 1998 until December 31 2006.

We excluded individuals with a diagnosis of dementia during January 1 1998--December 31 2006; a new diagnosis of hypothyroidism between January 1 2007 and December 31 2015; a diagnosis of hyperthyroidism or thyroid cancer during January 1 1998--December 31 2006, and with dispensed prescription of levothyroxine on two or more occasions in these diagnoses during July 1 2005--December 31 2006; individuals below 45 years of age at January 1 2007; and individuals with a dispensed prescription of levothyroxine on only one occasion during July 1 2005--December 31 2006. In total, 156,104 individuals (89,251 men and 66,853 women), aged ≥ 45 years were included (see Supplementary Fig. 1!).

The exposition was at least two dispensed prescription of levothyroxine (H03AA01) during July 1 2005--December 31 2006, aged 45 years of age or above and alive at January 1 2007. Individuals without a dispensed prescription were used as reference group.

The outcome was defined as a diagnosis of dementia according to ICD-10 classification in electronic patient records from hospitals, or from the Death register, and was used as primary outcome (F00 Alzheimer's dementia, F01 Vascular dementia, F02 Dementia in other diseases classified elsewhere, F03 Unspecified dementia, F10.7A Alcohol dementia, F10.97Alcohol use, unspecified with alcohol-induced persisting dementia or G30 Alzheimer's disease). We categorized dementia as Alzheimer's dementia (AD; F00 and G30), vascular dementia (VaD; F01) or other types of dementia (remaining diagnoses as listed above). For the primary outcome, time to diagnosis of dementia between January 1 2007 and December 31 2015 was registered. Individuals were also divided into the following pre-specified age-groups: 45--64, 65--84, and [\> ]{.ul}85 years. Individuals \< 45 years of age were excluded. Educational level was categorized according to pre-specification as ≤ 9 years (partial or complete compulsory schooling), 10--12 years (partial or complete secondary schooling) and \> 12 years (college and/or university studies). Country of birth was classified as born in Sweden or foreign born. Marital status was classified as married, unmarried, divorced or widowed. The neighborhood socioeconomic status (SES) areas were categorized into three groups according the neighborhood index: \> one standard deviation (SD) below the mean (high SES or low deprivation level), \> one SD above the mean (low SES or high deprivation level), and within one SD of the mean (middle SES or deprivation level).

The following related disorders were used as covariates (with ICD-10 codes): hypertension (I10--15); coronary heart disease (CHD; I20--25); congestive heart failure (CHF; I50 or I110); cerebrovascular diseases (CVD; I60--69); obesity (E65--E68); diabetes mellitus (E10--14); chronic obstructive pulmonary disease (COPD; J40--J47); depression (F32--F34, F38--F39); anxiety disorders (F40--41); and alcoholism and related disorders (F10 and K70).

Cardiovascular medication was recorded, with at least two dispensed prescription of the following drugs: loop diuretics (C03C), thiazides (C03A, C03B, C03E, C09B and C09DA), potassium-saving agents (C03D), beta-1-selective beta-blockers (C07AB and C07FB), non-selective beta-blockers (C07AA and C07AG), heart-active calcium channel blockers (C08DA), vessel-active calcium channel blockers (C08CA and C08DB), ACE inhibitors (C09AA and C09BA), angiotensin-receptor blockers (ARBs; C09CA, C09DA and C09DB), statins (C10AA) and anticoagulants (B01AA).

Descriptive data were shown as numbers and percentages, and with differences between individuals with incident dementia vs those without dementia shown as *p* values obtained from chi-square test. Cox regression with hazard ratios (HRs) and 95% confidence interval (95% CI), using time to dementia as the outcome, was used in follow-up analyses for patients with levothyroxine treatment compared to those without this, for all individuals and also categorized by sex. We used the following regression models: Model 1 adjusted for age; Model 2 adjusted for age, educational level, immigrant status, marital status, and neighborhood deprivation; Model 3 as Model 2 + comorbidities; and Model 4 as Model 3 + cardiovascular medication. In subgroup analyses, we analyzed dementia diagnosed as AD, VaD or other types of dementia. Furthermore, as risk factors for dementia differ over age, we also analyzed patients in the following age strata: 45--64 years of age, 65--84 years of age, and 85 years of age and above.

A two-sided *p* value of \< 0.01 was considered statistically significant for variables at baseline owing to multiple testing, and \< 0.05 for variables in the regression analyses. All analyses were performed in SAS 9.4.

Results {#Sec3}
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Characteristics of the study population (*n* = 156,104 individuals; 89,251 men and 66,853 women) are shown in Table [1](#Tab1){ref-type="table"}. In total, 9054 dementia diagnoses were recorded (5.8%), 4486 among men (5.0%) and 4568 (6.8%) among women. Mean follow-up was 5.4 years in the total sample, in the age-group 45--64 years 7.4 years, in the age-group 65--84 years 5.7 years, and in the age-group 85 years and above 3.0 years. Total person-years were in the whole sample 836,270 years and, in the age-groups 45--64, 65--84 and 85 years and above, 199,429, 525,186 and 111,655 years, respectively. Among individuals with dementia there were more women. Individuals with dementia were also older, had lower educational level, were less often married, had more often registered diagnoses of CHD, stroke, and depression, less often registered diagnoses of obesity and COPD, and were less often treated with anticoagulants. There were only small differences in regard to dispensed cardiovascular drugs, with higher rate of loop diuretics and lower rate of ARBs among dementia patients (Supplementary Table [1](#Tab1){ref-type="table"}).Table 1Baseline data of patients with atrial fibrillation and with or without levothyroxine treatment, and number of incident cases of dementia during follow-upPopulationDementia eventsWithout dementia*P* value\*No.%No%No%Total population156,1049054147,050Exposition\< 0.001 Levothyroxine treatment12,9788.38789.712,1008.2 No levothyroxine treatment143,12691.7817690.3134,95091.8Gender\< 0.001 Males89,25157.2448649.584,76557.6 Females66,85342.8456850.562,28542.4Age (years)\< 0.001 45--6426,91917.22092.326,71018.2 65--8491,73258.8617568.285,55758.2 ≥ 8537,45324.0267029.534,78323.7Educational level\< 0.001 ≤ 976,26448.9471952.171,54548.7 10--1236,01723.1202322.333,99423.1 \> 1243,82328.1231225.541,51128.2Immigrant status0.2674 Born in Sweden140,22489.8810289.5132,12289.8 Foreign born15,88010.295210.514,92810.2Marital status\< 0.001 Married85,47454.8432247.781,15255.2 Not married70,63045.2473252.365,89844.8Neighborhood deprivation\< 0.001 Low17,34711.196610.716,38111.1 Middle78,93850.6430647.674,63250.8 High18,67012.0108512.017,58512.0 Unknown41,14926.4269729.838,45226.1Hospital diagnosis Hypertension43,85428.1259228.641,26228.10.2428 CHD43,11127.6264629.240,46527.5\< 0.001 Heart failure40,50225.9229425.338,20826.00.1734 Stroke25,61016.4180820.023,80216.2\< 0.001 Obesity14540.9310.314231.0\< 0.001 Diabetes17,62311.3101211.216,61111.30.7289 COPD10,9987.05556.110,4437.1\< 0.001 Depression35052.23143.531912.2\< 0.001 Anxiety21721.41481.620241.40.0418 Alcoholism and related disorders29321.91822.027501.90.3407*CHD* coronary heart disease, *COPD* chronic obstructive pulmonary disease\**P* value was calculated based on chi-square test

Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} show Cox regression models for incident dementia for subjects with levothyroxine treatment vs. subjects without treatment, categorized by sex and also for men and women combined. Table [2](#Tab2){ref-type="table"} shows results in four models, while in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} only fully adjusted models are shown. Table [3](#Tab3){ref-type="table"} is categorized by age-groups, and Table [4](#Tab4){ref-type="table"} is categorized by type of dementia. We did not observe any association of levothyroxine therapy with incident dementia.Table 2Cox regression of dementia diagnosis among men (*n *= 89,251) and women (*n* = 66,853) with atrial fibrillation HR and with or without levothyroxine treatmentModel 1Model 2Model 3Model 4HR95% CIHR95% CIHR95% CIHR95% CIMen Levothyroxine treatment1.040.89--1.221.030.87--1.201.010.86--1.191.010.86--1.19 No treatmentRefRefRefRefWomen Levothyroxine treatment1.070.98--1.161.040.96--1.141.040.96--1.131.040.95--1.13 No treatmentRefRefRefRefAll^a^ Levothyroxine treatment1.070.99--1.151.040.97--1.121.030.96--1.121.030.96--1.11 No treatmentRefRefRefRef*Model 1* adjusted for age, *Model 2* adjusted for age, educational level, immigrant status, marital status, and neighborhood deprivation, *Model 3* Model 2 + comorbidities, *Model 4* Model 3 + cardiovascular medications^a^Gender was added in the Model 2, Model 3, and Model 4Table 3Cox regression of dementia diagnosis among men (*n* = 89,251) and women (*n* = 66,853) with atrial fibrillation HR and with or without levothyroxine treatment in different age-groups in fully adjusted modelAged 45--64 yearsAged 65--84 yearsAged 85 + yearsHR95% CIHR95% CIHR95% CIMen Levothyroxine treatment1.840.68--5.001.010.84--1.220.970.71--1.34 No treatmentRefRefRefWomen Levothyroxine treatment0.710.26--1.951.060.95--1.180.990.86--1.14. No treatmentRefRefRefAll^a^ Levothyroxine treatment1.050.51--2.151.050.95--1.150.990.87--1.13 No treatmentRefRefRef*Full Model* adjusted for age, educational level, immigrant status, marital status, neighborhood deprivation, comorbidities, and cardiovascular medications^a^Gender was added in the fully adjusted modelTable 4Cox regression of dementia diagnosis among men (*n* = 89,251) and women (*n* = 66,853) with atrial fibrillation HR and with or without levothyroxine treatment in different dementia groups in fully adjusted modelAlzheimer's diseaseVascular dementiaOthersHR95% CIHR95% CIHR95% CIMen Levothyroxine treatment1.050.78--1.431.210.92--1.610.870.68--1.12 No treatmentRefRefRefWomen Levothyroxine treatment1.040.88--1.231.030.86--1.241.050.93--1.18 No treatmentRefRefRefAll^a^ Levothyroxine treatment1.050.91--1.211.080.93--1.261.010.91--1.12 No treatmentRefRefRef*Full Model* adjusted for age, educational level, immigrant status, marital status, neighborhood deprivation, comorbidities, and cardiovascular medications^a^Gender was added in the fully adjusted model
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The main finding of this study was that levothyroxine treatment in AF patients was not associated with different risk of incident dementia. This was true for men and women, and also when divided by age-groups and type of dementia.

Our results seem to confirm the conclusion in an earlier review that there is no association between cognitive disturbances and dementia due to thyroid dysfunction \[[@CR18]\]. However, there are studies challenging this conclusion. In a study of AF patients in Swedish primary care, a lower risk of dementia was found in women with hypothyroidism and levothyroxine treatment, while no such association was found in men and women with levothyroxine treatment but without a diagnosis of hypothyroidism \[[@CR19]\]. Besides, in animal models an association between treatment with thyroid hormones and an improved brain function has been shown \[[@CR6], [@CR7]\]. In contrast, there are other studies showing an increased risk of cerebrovascular diseases associated with treated hypothyroidism \[[@CR1], [@CR2]\]. The reason for this discrepancy between studies is unclear, even if differences in methodology used, and populations included, could contribute to this. However, more studies on this topic are needed, including studies with levels of thyroid hormones.

In regard to comorbidities, individuals with incident dementia have been shown to more often be registered with some diagnoses, also known as risk factors for dementia, i.e. CHD \[[@CR20]\], stroke \[[@CR21]\], diabetes \[[@CR22], [@CR23]\], and depression \[[@CR24], [@CR25]\]. Some cardiovascular drugs, including anticoagulant treatment and some antihypertensive drugs, have also been shown to be associated with a lower risk of dementia among AF patients \[[@CR26], [@CR27]\]. However, adjusting for these factors only changed the HR estimates marginally.

There are several limitations of this study which must be kept in mind when interpreting the results. We did not have access to levels of thyroid hormones in the study, which could be of importance in further studies. Thus, we could not identify patients with over- or under-treatment with levothyroxine. As this is an observational study, there may be residual confounding present, and the result may be affected by biases such as competing risks, i.e. patients may die due to other causes before getting a dementia diagnosis, or survival treatment selection bias \[[@CR28]\]. Besides, as dementia develops over a period of many years the results of the setting of the diagnosis in relation to time may differ. We included patients with AF registered in hospital care, however, both from in-patient clinics and open care. Another study showed that 12% of all registered AF patients in Stockholm County were only registered with a diagnosis in primary health care, and 9% in ambulatory specialist care, including hospital out-patient clinics \[[@CR29]\]. Clinical diagnoses were taken from hospital care, while most diagnosis, i.e. hypertension, diabetes, COPD, depression and anxiety, will be underrepresented as most patients are cared for these diseases in primary care \[[@CR30]\]. We included patients with levothyroxine treatment recorded on at least two occasions, to ensure that this was a long-term treatment. However, we had data neither on levothyroxine treatment before 2005 nor on treatment duration. Our intention was to study patients with levothyroxine treatment with and without a diagnosis of hypothyroidism, but as most patients with this diagnosis are cared for in primary care only, a smaller part was identified with this diagnosis (1711 individuals or 13.8% of all with levothyroxine treatment). In the present study, we only had access to diagnoses of hypothyroidism in the Inpatient Register, while no diagnoses from primary care are included, and we had no possibility to identify patients with levothyroxine treatment without a diagnosis of hypothyroidism. In an earlier, smaller study (*n* = 12,057) of AF patients in primary care, as much as 35% of the patients, could not be identified with a diagnosis of hypothyroidism \[[@CR19]\]. Moreover, AF could not be classified as paroxysmal, persistent or permanent and heart rhythm could not be classified as sinus rhythm or fibrillation rhythm. Additionally, we had not access to data on kidney function. Besides, we have chosen not to report results of co-morbidities and cardiovascular medications used for adjustment, as we are analyzing these factors in other sub-studies, and including them here would go far beyond the main topic of the actual study.

In conclusion, we found no significant differences in incident dementia among AF patients with or without levothyroxine treatment. However, as previous studies show divergent results, it is of interest to perform further studies within this area. Furthermore, it would also be of interest to study the general potential effect of levothyroxine in relation to incident dementia, and not restrict future studies to patients with AF only. Yet, levothyroxine seems to be safe regarding dementia in patients with AF and also in combination with many cardiovascular pharmacotherapies.
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